.Attributes Medication, Released online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Viewpoint calls for introduction of clients with MASLD and size of liver outcomes in cardio-- renal-- metabolic trials, when data recommend mechanistically tenable advantages and clinical security-- as well as outlines factors for trial style as well as regulative commendation.